Axsome Therapeutics

Axsome Therapeutics reported that AUVELITY is seeing accelerated prescription growth with about 3,800 new prescriptions per week and that the agitation in Alzheimer’s indication is the fastest-growing share. The company has roughly $320 million in cash and equivalents, a quarterly cash burn of about $25 million, and sees operational leverage as revenue is expected to grow faster than expenses. Axsome reaffirmed a conservative model with a potential peak sales estimate of $8 billion, is running five phase‑III studies (including SUMMIT for smoking cessation and AXS-12 with a PDUFA date of May 1, 2027), and expects further commercial and market-access growth. Management cited political risks such as Medicare negotiations and the challenge of converting initial prescription gains into sustainable revenue growth. » Więcej na de.investing.com

Axsome highlighted accelerated commercialization of AUVELITY at the Cantor Healthcare Conference; the drug generated $180 million in Q2 2026 revenue (annualized $720 million) with a market share below 0.25%. The company raised its peak sales forecast for AUVELITY to over $8 billion, of which about $4 billion is attributed to MDD, and expects additional potential from the agitation in Alzheimer’s indication. Axsome has doubled its field force to 600 staff, reports positive early feedback on ADA (rapid onset, good tolerability) and notes broad reimbursement. Key pipeline catalysts are top-line data for solriamfetol in binge-eating disorder (Q4 2026) and a PDUFA date for AXS-12 in narcolepsy on May 1, 2027. » Więcej na de.investing.com

At the Wells Fargo Healthcare Conference, Axsome reported a stronger commercial base driven by AUVELITY, whose annualized revenue at the end of Q2 was about $750 million and whose new prescriptions are rising sharply. The company had roughly $330 million in cash at the end of Q2 and is targeting positive cash flow, while sales investments in H2 2024 are expected to provide operational leverage. The launch of AUVELITY for Alzheimer-related agitation is underway and shows early demand in long-term inpatient care. The pipeline includes an NDA under FDA review for AXS-12 (PDUFA May 1, 2027) and several phase III programs (binge eating, shift work disorder, ADHD) that offer further growth potential. » Więcej na de.investing.com